Quarterly report pursuant to Section 13 or 15(d)

Segments (Tables)

v3.5.0.2
Segments (Tables)
9 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
Operations and Assets for Operating Segments and Geographic Information
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the three months ended September 30,
 
For the nine months ended September 30,
(In thousands)
2016
 
2015
 
2016
 
2015
Revenue from services:
 
 
 
 
 
 
 
Pharmaceutical
$

 
$
160

 
$

 
$
192

Diagnostics
259,025

 
103,739

 
777,559

 
107,597

Corporate

 
20

 

 
140

 
$
259,025

 
$
103,919

 
$
777,559

 
$
107,929

Product revenues:
 
 
 
 
 
 
 
Pharmaceutical
$
20,569

 
$
20,765

 
$
63,275

 
$
59,066

Diagnostics

 

 

 

Corporate

 

 

 

 
$
20,569

 
$
20,765

 
$
63,275

 
$
59,066

Revenue from transfer of intellectual property:
 
 
 
 
 
 
 
Pharmaceutical
$
18,441

 
$
18,350

 
$
105,338

 
$
48,552

Diagnostics

 

 

 

Corporate

 

 

 

 
$
18,441

 
$
18,350

 
$
105,338

 
$
48,552

Operating income (loss):
 
 
 
 
 
 
 
Pharmaceutical
$
(18,593
)
 
$
5,300

 
$
15,422

 
$
(36,861
)
Diagnostics
3,098

 
(1,961
)
 
11,117

 
(17,961
)
Corporate
(8,128
)
 
(11,562
)
 
(49,414
)
 
(34,444
)
Less: Operating loss attributable to noncontrolling interests

 

 

 
(1,281
)
 
$
(23,623
)
 
$
(8,223
)
 
$
(22,875
)
 
$
(90,547
)
Depreciation and amortization:
 
 
 
 
 
 
 
Pharmaceutical
$
6,994

 
$
2,775

 
$
12,841

 
$
6,902

Diagnostics
18,818

 
9,602

 
59,711

 
13,103

Corporate
20

 
22

 
60

 
68

 
$
25,832

 
$
12,399

 
$
72,612

 
$
20,073

Net income (loss) from investment in investees:
 
 
 
 
 
 
 
Pharmaceutical
$
399

 
$
(3,502
)
 
$
(5,643
)
 
$
(6,067
)
Diagnostics
(1,213
)
 

 
496

 

Corporate

 

 

 

 
$
(814
)
 
$
(3,502
)
 
$
(5,147
)
 
$
(6,067
)
Revenues:
 
 
 
 
 
 
 
United States
$
259,221

 
$
104,358

 
$
777,703

 
$
109,359

Ireland
20,594

 
22,308

 
114,526

 
53,807

Chile
9,936

 
7,779

 
26,516

 
22,929

Spain
3,910

 
3,447

 
12,257

 
12,303

Israel
3,699

 
4,154

 
12,862

 
14,309

Mexico
675

 
988

 
2,308

 
2,840

 
$
298,035

 
$
143,034

 
$
946,172

 
$
215,547


(In thousands)
September 30,
2016
 
December 31,
2015
Assets:
 
 
 
Pharmaceutical
$
1,318,377

 
$
1,234,752

Diagnostics
1,412,726

 
1,421,034

Corporate
68,924

 
143,402

 
$
2,800,027

 
$
2,799,188

Goodwill:

 

Pharmaceutical
$
257,570

 
$
251,225

Diagnostics
442,956

 
492,123

Corporate

 

 
$
700,526

 
$
743,348